Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study

Abstract

Background: Uncomplicated acute rhinosinusitis (ARS) is usually a self-limiting inflammatory condition often treated with antibiotics.

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

“…186 Randomized, placebo-controlled blinded trials have evaluated the role of various INCSs in managing the duration and severity of ARS symptoms, as adjuvant therapies to antibiotic-based regimens, and more recently as monotherapies. 188,189 The latest INCS trials have used either fluticasone propionate 110 μg daily or twice daily or mometasone furoate 200 μg daily or twice daily to reduce daily impact of major ARS symptoms. 188,189 Although an early trial using budesonide demonstrated only minimal improvement with INCS, 186 results from subsequent trials suggest modest but significant improvements in symptom control with hastened onset of relief, when pairing INCS with antibiotics.…”

“…188,189 The latest INCS trials have used either fluticasone propionate 110 μg daily or twice daily or mometasone furoate 200 μg daily or twice daily to reduce daily impact of major ARS symptoms. 188,189 Although an early trial using budesonide demonstrated only minimal improvement with INCS, 186 results from subsequent trials suggest modest but significant improvements in symptom control with hastened onset of relief, when pairing INCS with antibiotics. [188][189][190][191][192][193][194] A Cochrane review meta-analysis, which included 1943 participants from 4 studies, arrived at a similar conclusion: symptoms in patients receiving INCS, particularly higher-dose treatments, were more likely to resolve or improve than in placebotreated patients.…”

Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper

“…Also, the reduction of the inflammatory reaction of the nasal mucosa by INCS may shorten the duration and decrease the severity of symptoms in viral upper respiratory tract infections. Although current evidence does not support the use of INCS for symptomatic relief of the common cold, 67 INCS are effective in reducing the total symptom score in adults suffering from acute postviral rhinosinusitis 20,68,69 …”

Effects of Fluticasone Furoate on Clinical and Immunological Outcomes (IL-17) for Patients With Nasal Polyposis Naive to Steroid Treatment

“…The nasal spray formulation of FF is a highly potent corticosteroid approved for therapeutic use in seasonal allergic rhinitis and perennial allergic rhinitis in Canada. 19-21 Subjects in this study had endoscopically verified bilateral nasal polyps, with a mean total bilateral grade score of approximately 5.00 and achieved reduction of their polyp volume and related nasal symptoms with the use of this intranasal corticosteroid (INCS). Although we have evaluated a very small group of patients, it seems appropriate to consider that the clinical benefit was better for the allergic subjects.…”